دورية أكاديمية
Changes in tryptophan breakdown associated with response to multimodal treatment in depression.
| العنوان: | Changes in tryptophan breakdown associated with response to multimodal treatment in depression. |
|---|---|
| المؤلفون: | Reininghaus EZ; Clinical Division of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria., Lenger M; Clinical Division of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria., Schönthaler EMD; Clinical Division of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria., Fellendorf FT; Clinical Division of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria., Stross T; Clinical Division of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria., Schwarz M; Institute of Laboratory Medicine, University Hospital, Ludwig-Maximilian University (LMU), Munich, Munich, Germany., Moll N; Institute of Laboratory Medicine, University Hospital, Ludwig-Maximilian University (LMU), Munich, Munich, Germany., Reininghaus B; Clinical Division of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria., Dalkner N; Clinical Division of Psychiatry and Psychotherapeutic Medicine, Medical University of Graz, Graz, Austria. |
| المصدر: | Frontiers in psychiatry [Front Psychiatry] 2024 Jun 21; Vol. 15, pp. 1380620. Date of Electronic Publication: 2024 Jun 21 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101545006 Publication Model: eCollection Cited Medium: Print ISSN: 1664-0640 (Print) Linking ISSN: 16640640 NLM ISO Abbreviation: Front Psychiatry Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Switzerland : Frontiers Research Foundation, 2010- |
| مستخلص: | Background: Research on depression showed that dysregulations in tryptophan (TRP), kynurenine (KYN), and its KYN pathway metabolites are key aspects in the development and maintenance of depressive symptoms. In our previous reports, we described sex-specific changes in TRP breakdown as well as changes in KYN and KYN/TRP in association with treatment response and inflammatory and metabolic parameters. However, results of treatment effects on KYN pathway metabolites as well as how pathway changes are related to treatment response remain sparse. Objective: We investigated potential changes of KYN and KYN pathway metabolites in association with therapeutic response of individuals with depression during a six-week multimodal psychiatric rehabilitation program. Methods: 87 participants were divided into treatment responders and non-responders (48 responders, 39 non-responders; 38 male, 49 female; M Results: Non-responders exhibited higher levels of 3-Hydroxyanthralinic acid (3-HAA), nicotinic acid (NA), and 3-HAA/KYN, independently of measurement time. NA levels decreased, while 3-HAA levels increased over time in both groups, independently of treatment response. 3-HK/KYN levels decreased, while KYN levels increased in non-responders, but not in responders over time. Discussion: The results indicate that some compounds of the KYN pathway metabolites can be altered through multimodal long-term interventions in association with treatment response. Especially the pathway degrading KYN further down to 3-HAA and 3-HK/KYN might be decisive for treatment response in depression. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Reininghaus, Lenger, Schönthaler, Fellendorf, Stross, Schwarz, Moll, Reininghaus and Dalkner.) |
| References: | Psychoneuroendocrinology. 2018 Aug;94:25-30. (PMID: 29753175) Front Psychiatry. 2019 Feb 21;10:74. (PMID: 30846946) Commun Med (Lond). 2022 May 12;2(1):49. (PMID: 35603278) J Nutr. 2015 Apr;145(4):701-7. (PMID: 25833774) Drug Discov Today. 2016 Feb;21(2):315-24. (PMID: 26589832) CNS Neurol Disord Drug Targets. 2019;18(2):124-140. (PMID: 30451122) J Psychosom Res. 2017 Aug;99:1-7. (PMID: 28712413) Pacing Clin Electrophysiol. 2010 Sep;33(9):1131-40. (PMID: 20487354) Obesity (Silver Spring). 2014 Jan;22(1):195-201. (PMID: 23625535) J Clin Med. 2021 Jun 04;10(11):. (PMID: 34199713) Pharmacol Rep. 2020 Apr;72(2):449-455. (PMID: 32162182) Transl Psychiatry. 2016 Aug 02;6(8):e865. (PMID: 27483383) Brain Behav Immun. 2020 Jul;87:404-412. (PMID: 31978524) PLoS One. 2017 Feb 27;12(2):e0172699. (PMID: 28241062) Brain Behav Immun. 2003 Feb;17 Suppl 1:S119-24. (PMID: 12615197) Behav Res Methods. 2009 Nov;41(4):1149-60. (PMID: 19897823) Biol Psychiatry. 2003 Nov 1;54(9):906-14. (PMID: 14573318) Rev Neurosci. 2022 Sep 05;34(3):313-324. (PMID: 36054612) Neurosci Biobehav Rev. 2020 Nov;118:514-523. (PMID: 32853625) Nat Rev Dis Primers. 2016 Sep 15;2:16065. (PMID: 27629598) Mol Psychiatry. 2021 Aug;26(8):4158-4178. (PMID: 33230205) Brain Behav Immun. 2012 Aug;26(6):979-87. (PMID: 22683764) Mult Scler Relat Disord. 2020 Nov;46:102533. (PMID: 33010585) J Psychiatr Res. 2015 Jul-Aug;66-67:118-26. (PMID: 26009299) J Clin Med. 2022 Apr 29;11(9):. (PMID: 35566641) Front Behav Neurosci. 2022 Sep 12;16:987697. (PMID: 36172468) J Psychiatr Res. 2015 Sep;68:316-28. (PMID: 26028548) Psychoneuroendocrinology. 2011 Apr;36(3):426-36. (PMID: 21041030) Psychosom Med. 2016 May;78(4):384-8. (PMID: 27128110) Clin Exp Pharmacol Physiol. 2009 Apr;36(4):425-35. (PMID: 19018805) J Affect Disord. 2007 Feb;98(1-2):143-51. (PMID: 16952400) Clin Psychopharmacol Neurosci. 2020 Nov 30;18(4):507-526. (PMID: 33124585) Neuropsychiatr Dis Treat. 2011;7:431-9. (PMID: 21792309) J Child Psychol Psychiatry. 2010 Aug;51(8):935-43. (PMID: 20406333) Antioxidants (Basel). 2021 Nov 10;10(11):. (PMID: 34829665) PLoS One. 2015 Sep 14;10(9):e0137022. (PMID: 26368809) Nat Rev Neurosci. 2012 Jul;13(7):465-77. (PMID: 22678511) Gastroenterology. 2017 Dec;153(6):1504-1516.e2. (PMID: 28827067) Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt C):234-249. (PMID: 28595944) Psychoneuroendocrinology. 2017 Jul;81:144-150. (PMID: 28482311) Pteridines. 2015 Jun;26(2):79-84. (PMID: 26251562) Neuropsychopharmacology. 2024 Feb;49(3):584-592. (PMID: 37735504) PLoS One. 2010 Jul 28;5(7):e11825. (PMID: 20689575) Int J Mol Sci. 2022 Jul 31;23(15):. (PMID: 35955633) Psychosom Med. 2003 Jul-Aug;65(4):665-71. (PMID: 12883120) Psicothema. 2023 Feb;35(1):21-29. (PMID: 36695847) Brain Behav Immun. 2020 Jan;83:239-247. (PMID: 31698012) Neurosci Biobehav Rev. 2018 Sep;92:477-485. (PMID: 29940237) J Neuroinflammation. 2005 Jul 26;2:16. (PMID: 16042813) Bipolar Disord. 2014 Jun;16(4):432-40. (PMID: 24330408) Brain Behav Immun Health. 2022 Oct 21;26:100537. (PMID: 36339964) J Affect Disord. 2002 Dec;72(3):237-41. (PMID: 12450640) Brain Behav Immun. 2002 Oct;16(5):590-5. (PMID: 12401473) J Clin Psychopharmacol. 2002 Feb;22(1):86-90. (PMID: 11799348) Transl Psychiatry. 2017 May 2;7(5):e1115. (PMID: 28463241) Biomolecules. 2022 Jul 18;12(7):. (PMID: 35883554) |
| فهرسة مساهمة: | Keywords: affective disorder; depression; kynurenine; kynurenine pathway; multimodal treatment |
| تواريخ الأحداث: | Date Created: 20240708 Latest Revision: 20240709 |
| رمز التحديث: | 20240709 |
| مُعرف محوري في PubMed: | PMC11224482 |
| DOI: | 10.3389/fpsyt.2024.1380620 |
| PMID: | 38974918 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-0640 |
|---|---|
| DOI: | 10.3389/fpsyt.2024.1380620 |